Skip to content
value.today
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is listed today as Ensysce Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 8 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Ensysce Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$77 MPrivate placement after listing$50 to $250 million

Ensysce Biosciences, Inc.: Private sale, Aug 2026

Investors in this round

44 investors had bought by the notice of Aug 20, 2026: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$77 M of $77 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,289,946
Finders' fees
$200,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • James Lynn Morrison · Executive Officer, Director
  • Adam Lynn Levin · Director
  • Bob Lynn Gower · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • UBS Securities LLC (CRD 000007654) · New York, New YorkSold in all US states, and outside the US
  • Cantor Fitzgerald & Co. (CRD 000000134) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On the amounts: “Of Total Amount Sold, $38.6 million is subject to certain contingencies”

Signed by Dr. Lynn Kirkpatrick, Ceo. Newest notice filed Aug 20, 2026. Read the notice at the SEC.

equitySEC
Apr 2025$2 MPrivate placement after listing$2 to $10 million

Ensysce Biosciences, Inc.: Private sale, Apr 2025

Investors in this round

8 investors had bought by the notice of Apr 25, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$154,001
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Lee Lynn Rauch · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Consists of cash compensation for a separate warrant inducement and issuance of warrants to purchase 44,126 shares of common stock.”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Apr 25, 2025. Read the notice at the SEC.

optionsSEC
Mar 2025$1 MPrivate placement after listingUnder $2 million

Ensysce Biosciences, Inc.: Private sale, Mar 2025

Investors in this round

8 investors had bought by the notice of Apr 14, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$142,950
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Lee Lynn Rauch · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Consists of amounts received in a concurrent registered offering of $77,000 (commission), $50,000 (expense), $15,950 (clearing fee) and warrants to purchase 22,063 shares of common stock.”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Apr 14, 2025. Read the notice at the SEC.

optionsSEC
Aug 2024$5 MPrivate placement after listing$2 to $10 million

Ensysce Biosciences, Inc.: Private sale, Aug 2024

Investors in this round

4 investors had bought by the notice of Sep 12, 2024: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$454,845
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Lee Lynn Rauch · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Includes commissions & fees received in a concurrent registered offering of $353,895, $35,000 (non-accountable expense), $50,000 (legal), $15,950 (clearing fees) and warrants to purchase 752,969 shares of common stock.”
  • On the amounts: “Includes totals from 3 public and non-public offerings simultaneously closed; specific consideration was not delineated for the non-public offerings, which involved warrants for up to 29,469,869 shares of common stock.”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Sep 12, 2024. Read the notice at the SEC.

optionsSEC
Feb 2024$5 MPrivate placement after listing$2 to $10 million

Ensysce Biosciences, Inc.: Private sale, Feb 2024

Investors in this round

4 investors had bought by the notice of Feb 21, 2024: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$265,950
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Lee Lynn Rauch · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “(i) $200,000 cash fee, (ii) $20,000 for non-accountable expenses, (iii) $30,000 for legal expenses, (iv) $15,950 for clearing fees and (v) warrants to purchase 252,123 shares (7% of the shares placed) at an exercise price of $1.6375 per share”
  • On the amounts: “(i) warrants to purchase 7,203,504 shares of common stock issued in return of exercise of outstanding warrants to purchase 3,601,752 shares of common stock and (ii) warrants to the placement agent for 252,123 shares”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Feb 21, 2024. Read the notice at the SEC.

optionsSEC
Feb 2023$3 MPrivate placement after listing$2 to $10 million

Ensysce Biosciences, Inc.: Private sale, Feb 2023

Investors in this round

8 investors had bought by the notice of Mar 1, 2023: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$210,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Lee Lynn Rauch · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Warrants to purchase common stock to investors for up to 3,571,431 shares at $0.715/share and to designees of H.C. Wainwright & Co., LLC for up to 250,000 shares at $1.05/share in connection with a 2/2/2023 registered direct offering.”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Mar 1, 2023. Read the notice at the SEC.

optionsSEC
Jun 2022$4 MPrivate placement after listing$2 to $10 million

Ensysce Biosciences, Inc.: Private sale, Jun 2022

Investors in this round

3 investors had bought by the notice of Jul 8, 2022: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $8 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$200,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Lee Lynn Rauch · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Lake Street Capital Markets, LLC (CRD 164447) · broker-dealer Lake Street Capital Markets, LLC (CRD 164447) · Minneapolis, MinnesotaSold in NY

Remarks in the notice

  • On the amounts: “Amounts include an original issue discount in the amount of six percent (6%).”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Jul 8, 2022. Read the notice at the SEC.

debt, optionsSEC
Sep 2021$5 MPrivate placement after listing$2 to $10 million

Ensysce Biosciences, Inc.: Private sale, Sep 2021

Investors in this round

3 investors had bought by the notice of Oct 6, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $16 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$250,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D Lynn Kirkpatrick · Executive Officer, Director
  • David Lynn Humphrey · Executive Officer
  • Adam Lynn Levin · Director
  • Andrew Lynn Benton · Director
  • Bob Lynn Gower · Director
  • Curtis Lynn Rosebraugh · Director
  • Steve Lynn Martin · Director
  • William Lynn Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Lake Street Capital Markets, LLC (CRD 164447) · broker-dealer Lake Street Capital Markets, LLC (CRD 164447) · Minneapolis, MinnesotaSold in NY

Remarks in the notice

  • On the amounts: “Amounts include an original issue discount in the amount of six percent (6%).”

Signed by Dr. Lynn Kirkpatrick, President and CEO. Newest notice filed Oct 6, 2021. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Ensysce Biosciences, Inc., its revenue in fiscal 2025 came from these product and service lines: MPAR $5.07 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Ensysce Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Aug 2026

Products and services#

No products or services of Ensysce Biosciences, Inc. are on record.

Investors#

No investor of Ensysce Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Ensysce Biosciences, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ensysce Biosciences, Inc.
NameRoleNamed in
D Lynn KirkpatrickExecutive officerAug 2026
David Lynn HumphreyExecutive officerAug 2026
James Lynn MorrisonExecutive officerAug 2026
Adam Lynn LevinDirectorAug 2026
Bob Lynn GowerDirectorAug 2026
D Lynn KirkpatrickDirectorAug 2026
James Lynn MorrisonDirectorAug 2026
Steve Lynn MartinDirectorAug 2026
William Lynn ChangDirectorAug 2026
Andrew Lynn BentonDirectorApr 2025
Curtis Lynn RosebraughDirectorApr 2025
Lee Lynn RauchDirectorApr 2025

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.